We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

Cyclic Oxygen Therapy Effective for Chronic Skin Ulcerations

By HospiMedica International staff writers
Posted on 05 Jun 2018
Adjunctive cyclic oxygen therapy devices help close chronic wounds, including venous, diabetic, and pressure ulcers.

The AOTI (Oceanside, CA, USA) range of single-use Topical Wound Oxygen (TWO2) extremity chambers are used to apply pressurized oxygen (O2) directly to wound sites in cycles of 5 and 50 millibar (mb) within a sealed, humidified environment created by an inflatable plastic chamber and managed by an electro-mechanical therapy controller unit. More...
The blended therapies provide a far greater tissue O2 diffusion gradient, resulting in increased tissue oxygenation. The cyclical nature of O2 pressure also creates sequential compression that reduces peripheral edema and stimulates wound site perfusion.

Providing targeted oxygen destroys anaerobic pathogens, increase leukocyte function, reverses localized hypoxia, and stimulates collagen synthesis by enhancing fibroblast activity and promoting angiogenesis. The synergistic activity causes wound bed granulation, collagen tissue formation, enhance antibacterial activity, and suppression of bacterial growth, thus leading to new, healthy tissue, and faster healing of the wound. The single-use devices are easy to set-up and operate, and can be disposed of between treatments, eliminating any need for cleaning between patients.

“We are pleased that healthcare professionals around the world are recognizing more and more the clinical benefits of adding TWO2 therapy to existing wound care best practices, and that by helping completely heal chronic wounds greatly reduce the total cost of care, but more importantly improve the patient’s quality of life,” said Mike Griffiths, CEO and president of AOTI. “We are delighted to have helped heal the wounds of so many patients within their homes, and look forward to even greater adoption of TWO2 therapy in the future.”

Chronic ulcerations afflict 33 million people globally, with an ever-growing prevalence due to increasing diabetes and obesity rates, as well as an aging population. Wound types include venous leg ulcers (VLU) that can persist for decades, causing 70% of all leg ulcerations; diabetic foot ulcers (DFUs), which affect about 25% of diabetics during their lifetime; and pressure ulcers, which add a major burden both for the hospitalized patient and healthcare staff. Global expenditure for treating such chronic wounds is estimated to be in excess of USD 55 Billion annually, making it one of the most costly components of the health care system.

Related Links:
AOTI


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Tourniquet System
heidi– mein Tourniquet
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.